ERNST ALEXANDER
No ORCID on file
· 253 papers in corpus
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted cyanoanthranilamide derivatives, to the production and use thereof as medicaments for the treatment of diseases triggered by persistent angiogenesis. The inventive compounds can be used, for instance in …
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…
2004
The invention relates to substituted N-oxide anthranylamide derivatives, to the production thereof and to their use as medicaments for treating diseases that are triggered by persistent angiogenesis. The inventive compounds can be used in t…